Lifestyle Program for Congenital Heart Disease
(CHD-PALS V2 Trial)
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Research shows that physical activity is linked to better exercise capacity and quality of life in adults with congenital heart disease. Regular physical activity can improve aerobic fitness and may reduce health issues over time.
12345Research shows that home-based, self-selected exercise training is safe for adults with congenital heart disease, suggesting that similar lifestyle programs are generally safe for humans.
34567The CHD-PAL treatment is unique because it focuses on a lifestyle intervention that encourages physical activity specifically tailored for individuals with congenital heart disease, rather than relying on medication or surgery. This approach aims to improve exercise capacity and overall health through a structured physical activity program, potentially using telemedicine to enhance accessibility and convenience.
568910Eligibility Criteria
This trial is for young people aged 15-25 with moderate to complex congenital heart disease, who are patients at Nationwide Children's Hospital or Ohio State University. They must be able to speak and read English well, not have had recent major heart surgery, and can't already be very physically active or in another exercise program.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a 20-week videoconferencing-administered intervention including 9 sessions to increase physical activity and healthy living
Interim Follow-up
Participants' physical activity and TPB mechanisms are assessed 20 weeks post-intervention
Follow-up
Participants are monitored for safety and effectiveness after treatment